Negev Labs

Actual: Nov 1, 2022

Cunningham et al. publish "Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs" in ACS Chemical Neuroscience. Key findings: single-dose (R)-Ariadne (10 mg/kg) reversed motor deficits on par with L-DOPA in auxilin knockout PD mice — despite having NO dopamine receptor activity. Confirmed non-hallucinogenic (4-6x weaker Gq signaling vs DOM).

Why it matters: Remarkable finding: a non-dopaminergic compound matching L-DOPA efficacy in PD models. If this translates, it would be the first non-dopaminergic motor treatment for Parkinson's — avoiding dyskinesia, impulse control, and psychosis side effects of current L-DOPA/agonist therapies. The 1970s Bristol-Myers 500-patient dataset provides unusual historical clinical support.

Actual: Dec 11, 2024

Negev Labs emerges from stealth. Announces Ariadne Bio subsidiary (CEO: Shlomi Raz) targeting Parkinson's apathy with 4C-D/BL-3912A. Also announces ASRI licensing, Beckley ophthalmology acquisition, and Hadassah BrainLabs collaboration.

Why it matters: Public debut reveals the venture studio model and three distinct programmes. Shlomi Raz (founder of Eleusis, ex-Beckley President) brings deep psychedelic pharma experience and relationships to the Ariadne subsidiary.

Actual: Aug 1, 2025

Preclinical data published (CINP/IJNP 2025): HBL20017 is non-hallucinogenic (no head-twitch despite 5-HT2A agonism). Single dose reduced obsessive self-grooming in SAPAP3 knockout mice (gold-standard OCD model) within 48 hours, with effects persisting up to 42 days. Also alleviated head-body twitches, suggesting potential in tic disorders / Tourette's. Anti-obsessional efficacy confirmed in marble burying test.

Why it matters: 42-day single-dose durability is extraordinary — current OCD medications (SSRIs, clomipramine) require daily dosing and take weeks to show effect. If HBL20017's durability translates clinically, it would fundamentally change OCD treatment from chronic daily medication to intermittent dosing. The tic disorder signal expands the addressable market to Tourette's syndrome.

Actual: Dec 11, 2024

Negev Labs acquires Beckley Psytech's ophthalmology development programme (ELE-02, DOI analog for retinal 5-HT2A). Programme originated at Eleusis Therapeutics (Shlomi Raz), deprioritized by Beckley post-acquisition.

Why it matters: Revives a scientifically promising programme that was shelved for financial reasons. Topical 5-HT2A agonist eye drops for retinal degeneration is a unique mechanism with no competition in the psychedelic pharma space. Charles Nichols (LSUHSC, Eleusis scientific founder) published foundational work supporting this approach.